Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin Monotherapy in Type 2 Diabetes
NCT00121641Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2005
- Primary completion
- Aug 2006
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of saxagliptin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by AstraZeneca. Primary endpoint: Hemoglobin A1c Changes From Baseline at 24 weeks. Started Jul 2005; status: completed.
02
Drugs
saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00121641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121641.